NAD (Nicotinamide Adenine Dinucleotide): From a Metabolic Coenzyme to Homeostatic Regulation and Application Targets
NAD (Nicotinamide Adenine Dinucleotide): From a Metabolic Coenzyme to Homeostatic Regulation and Application Targets
NAD (nicotinamide adenine dinucleotide, Nicotinamide Adenine Dinucleotide), also known as Coenzyme I, is composed of nicotinamide, adenine, and two ribose units linked via a phosphodiester bond. It forms a reversible redox pair as oxidized NAD⁺ and reduced NADH, serving as an electron carrier in energy metabolic processes such as glycolysis, fatty-acid β-oxidation, and the tricarboxylic acid cycle. Meanwhile, as a cosubstrate of enzymes such as Sirtuins, PARP, CD38/157, and SARM1, it couples metabolic homeostasis with regulatory networks related to DNA damage responses, inflammation, and aging. Within the homeostatic framework of “NAD synthesis—consumption—recycling and regeneration,” NAD is both a key variable and analytical object in basic research and an important metabolic node for multiple disease-related intervention strategies.
Keywords: NAD; NAD⁺/NADH; NADP⁺/NADPH; salvage synthesis; Preiss-Handler; de novo synthesis; NAD-consuming enzymes; homeostasis; aging
I. Research History and Key Milestones
1.1 Early Discovery and Establishment of Redox Function
(1) 1906: Discovery of a key factor in fermentation
Arthur Harden and William John Young, while studying alcoholic fermentation, found that yeast extracts contain a heat-stable factor essential for fermentation (later incorporated into the concept of “coenzymes”), although its chemical structure was not yet defined at the time.
(2) 1936: Proposal of the hydride-transfer site
Heinrich Otto Wieland clarified the role of nucleotide coenzymes in hydride transfer and identified the nicotinamide moiety as the key site for redox reactions.
(3) 1938: Discovery of the vitamin precursor
Conrad Elvehjem discovered that nicotinamide is an important vitamin precursor of NAD⁺, laying the foundation for subsequent studies on NAD nutrition and biosynthetic sources.
1.2 Elucidation of Biosynthetic Pathways and Expansion of Regulatory Functions
(1) 1948: Discovery of a biosynthetic enzyme
Arthur Kornberg reported the first enzyme related to the NAD biosynthetic pathway, promoting systematic elucidation of NAD biosynthesis mechanisms.
(2) 1958: Elucidation of the Preiss-Handler pathway
Jack Preiss and Philip Handler elucidated the metabolic pathway by which nicotinic acid is converted to NAD (the Preiss-Handler pathway), defining key entry points by which different forms of vitamin B3 enter the NAD synthesis network.
(3) 1963: Pathway clues related to DNA repair
Pierre Chambon and colleagues found that the NAD-derived compound nicotinamide mononucleotide (NMN) can activate the DNA repair-related enzyme PARP, providing important evidence linking NAD to genome maintenance and stress repair.
1.3 Establishment of NAD as a Longevity and Metabolic Regulatory Node and the Rise of Translational Research
(1) After 2000: Confirmation of the cosubstrate role for Sirtuins
Shin-ichiro Imai and colleagues indicated that NAD⁺ can serve as a cosubstrate for the deacetylase Sirtuins, participating in networks of longevity and metabolic regulation.
(2) Recent years: Expansion of precursor interventions and disease-oriented research
The potential value of NAD⁺ precursors (such as NMN and NR) has been widely studied in aging-related phenotypes, neurodegenerative diseases, and tumor immunotherapy, with the evidence base largely focusing on restoration of metabolic homeostasis and reshaping of downstream regulatory pathways.
II. Molecular Features and Functional Positioning
2.1 Structural Composition and the Nature of Redox Activity
(1) Molecular composition
NAD consists of a dinucleotide backbone formed by nicotinamide, adenine, and two ribose units, with the ribose units linked via a phosphodiester bond.
(2) Major intracellular forms
NAD mainly exists in cells as NAD⁺ and NADH, which interconvert reversibly to match the redox requirements of different reactions.
(3) Chemical basis of hydride transfer
In typical dehydrogenation reactions, the substrate transfers a hydride (H⁻, equivalently carrying 2 electrons and 1 proton) to NAD⁺ to generate NADH, while another proton (H⁺) is released into solution, thereby achieving coupled transfer of electrons and protons.
2.2 From a Metabolic Coenzyme to a Regulatory Cosubstrate
(1) Metabolic level
As a universal electron carrier, NAD⁺/NADH determines the redox driving force and energy acquisition efficiency of multiple catabolic pathways.
(2) Regulatory level
NAD participates as a cosubstrate in multiple consumption-type reactions, extending its role from a recyclable coenzyme to a regulatory resource with net-consumption characteristics.
(3) Homeostatic level
When fluxes at the synthesis, consumption, and recycling ends shift, both the size of the NAD pool and the NAD⁺/NADH ratio can change coordinately, thereby influencing metabolic phenotypes, repair capacity, and cell-fate decisions.
III. Physiological Functions In Vivo and the Homeostatic Regulatory Framework
3.1 Classical Physiological Functions: Energy Metabolism and the Catabolic Main Line
(1) Electron carrier in catabolic pathways
NAD(H) participates in glycolysis, pyruvate oxidation, fatty-acid β-oxidation, and the tricarboxylic acid cycle, providing electron acceptor/donor pairing for dehydrogenation reactions and supporting electron flow through the respiratory chain.
(2) System-level effects of the NAD⁺/NADH ratio
When the overall pool size is relatively stable, metabolic stress often reshapes cellular metabolic phenotypes by altering the NAD⁺/NADH ratio, affecting pathway directionality and mitochondrial redox pressure.
(3) Functional division of labor with the NADP system
Structurally related NADP(H) mainly participates in anabolic reactions and oxidative-stress defense; NAD(H) mainly participates in catabolic reactions. Together they constitute a dual-system architecture for cellular redox homeostasis.
3.2 Regulatory Functions: NAD-Consuming Reactions, Recycling and Regeneration, and RNA Modifications
(1) NAD-consuming enzymes and pathway attributes
Sirtuins, PARP, CD38/157, and SARM1 consume NAD while mediating deacetylation/deacylation regulation, ADP-ribosylation, signaling-molecule metabolism, and neurodegeneration-related roles, respectively, causing NAD homeostasis to exhibit coexisting features of recycling use and net consumption.
(2) NAM recycling and the salvage synthesis loop
NAD degradation often produces nicotinamide (NAM), and NAM regenerates NAD through salvage synthesis pathways, thereby maintaining cellular NAD levels and flux balance.
(3) NAD⁺ cap modification and mRNA regulation
① NAD⁺ can appear as a non-canonical cap modification at the 5′ end of RNA, affecting mRNA stability and translation level.
② Eukaryotic systems have decapping mechanisms that remove the NAD⁺ cap (such as DXO-related processes), thereby regulating NAD-RNA levels.
③ NAD⁺ capping may occur via two modes, transcription-initiation capping and post-transcriptional capping, suggesting that its regulatory roles are context-dependent.
IV. Physicochemical Properties and Experiment-Related Notes
4.1 Physicochemical Properties Table
Item | Specification/Description |
Name | Nicotinamide Adenine Dinucleotide |
Aliases | NAD; Nadide; Coenzyme I; Coenzyme I; Coenzyme I (oxidized form) |
Molecular formula | C21H27N7O14P2 |
Molecular weight | 663.4 |
Appearance | White powder |
Melting point | 140–142°C |
Bulk density | 200–300 kg/m³ |
Solubility | 752.5 mg/mL |
pH | ~3.0 (50 mg/mL aqueous solution) |
Odor | Odorless |
Maximum absorption wavelength (λmax) | 260 nm |
Stability | Stable; hygroscopic; incompatible with strong oxidizing agents |
4.2 Experimental Key Points
(1) Control of sample and solution states
Based on its hygroscopicity and the acidic nature of its solutions, consistent conditions should be established for weighing, dissolution, buffering, and storage, and key batches should be validated for stability and recovery.
(2) Specificity boundaries of spectroscopic readings
Absorbance at 260 nm is a generic characteristic signal of nucleotide classes and may be affected by nucleic acids, nucleotides, and aromatic impurities in complex matrices; if used for quantification, blank/matrix controls should be set and linearity, specificity, and repeatability should be validated.
(3) Control of redox state
In experiments involving interconversion between NAD⁺ and NADH, the redox environment (dissolved oxygen, reducing/oxidizing agents, metal ions, light exposure, etc.) should be managed as key variables to reduce systematic errors caused by unintended redox drift.
V. Metabolic Pathways and NAD⁺-Enhancement Strategies
5.1 NAD Synthesis Pathways: Salvage, Preiss-Handler, and De Novo Synthesis
(1) Salvage pathway
NAM and NR can enter salvage synthesis via the shared intermediate NMN, and are ultimately converted to NAD⁺ catalyzed by NMNAT, forming a closed-loop flux system of consumption—recycling—regeneration.
(2) Preiss-Handler pathway
Nicotinic acid is converted to NAMN via NAPRT, then to NAAD via NMNAT, and finally to NAD⁺ catalyzed by NADS.
(3) De novo synthesis pathway
The tryptophan–kynurenine pathway and the aspartate pathway can generate quinolinic acid (QA) and enter downstream steps to produce NAD⁺; branch nodes (such as ACMSD-related steps) regulate intermediate flux allocation and affect NAD production efficiency.
5.2 NAD⁺-Enhancement Strategies: Stimulating Synthesis and Inhibiting Excessive Consumption
(1) Stimulating NAD⁺ synthesis
① Supplementing NAD⁺ precursors: NMN and NR are commonly used precursors; NA, NAM, and other vitamin B3-related molecules are also included. Different precursors differ in tissue distribution, metabolic conversion, and flux contribution.
② Enhancing the activity of key enzymes in the salvage pathway: NAMPT, as one of the key steps in salvage synthesis, can increase cellular NAD production flux when its activity is elevated; NAMPT may also be regulated by deacetylation.
③ Activating the NQO1-related route: NQO1 uses NADH as an electron donor to mediate quinone/hydroquinone conversion. Studies have proposed that changes in its activity correlate with NAD⁺ levels in liver and kidney, suggesting that activating NQO1 may increase cellular NAD⁺ levels and produce tissue-protective effects.
④ Reducing branch dissipation in de novo synthesis: ACMSD is located at a branch-control node in de novo synthesis; upregulation of its expression can reduce flux into the NAD synthesis main trunk, whereas downregulation or pharmacological inhibition can increase NAD⁺ levels in liver and kidney.
(2) Inhibiting excessive NAD⁺ consumption
① Target selection based on the relationship between Km and physiological concentration: NAD-consuming enzymes with Km values below the physiological concentration range of NAD⁺ (such as PARP-1, CD38, and SARM1) can markedly deplete NAD reserves when overactivated.
② Inhibiting PARP-related consumption: Under increased DNA-damage load, excessive PARP activation may cause depletion of NAD and ATP and trigger cell-death-related processes.
③ Inhibiting CD38/157-related consumption: CD38/157 mediates NAD hydrolysis and generates products such as NAM; its aging-associated upregulation and association with NAD decline have been frequently reported.
④ Inhibiting SARM1-related consumption: SARM1-mediated NAD consumption is associated with pathological processes in the nervous system such as axonal degeneration and is a key consumption-end target in discussions of neuroprotective strategies.
(3) Tiered setting of endpoint evaluations
① Molecular endpoints: total NAD, NAD⁺/NADH ratio, NAD metabolite profiles, key enzyme activities, or pathway readouts.
② Functional endpoints: improvements in energy metabolism, structure, and functional indicators relevant to the target tissue.
③ Safety endpoints: adverse events, organ-function indicators, and risks of interactions with underlying diseases/medications.
VI. Aladdin-Related Products
Product No. | Name | CAS No. |
Grade & Purity |
β-Nicotinamide adenine dinucleotide hydrate | 53-84-9 | ≥99%, purified by column chromatography | |
β-Nicotinamide adenine dinucleotide hydrate | 53-84-9 | ≥96.5%(HPLC), ≥96.5%(spectrophotometric assay), from yeast | |
β-Nicotinamide adenine dinucleotide hydrate | 53-84-9 | Moligand™, Grade AA-1 | |
β-Nicotinamide adenine dinucleotide hydrate | 53-84-9 | Moligand™, for cell culture, ≥96.5%(HPLC), ≥96.5%(spectrophotometric assay), from yeast | |
β-Nicotinamide adenine dinucleotide(NAD) | 53-84-9 | ≥98%, lyophilized powder | |
β-Nicotinamide adenine dinucleotide(NAD) | 53-84-9 | Moligand™, ≥97% | |
β-Nicotinamide adenine dinucleotide（NAD） | 53-84-9 | Moligand™, 10mM in Water | |
β-Nicotinamide adenine dinucleotide(NAD) | 53-84-9 | ≥99.5% | |
β-Nicotinamide adenine dinucleotide（NAD） | 53-84-9 | Moligand™, ≥95% | |
β-Nicotinamide adenine dinucleotide（NAD） | 53-84-9 | Moligand™, ≥98%(HPLC) | |
β-Nicotinamide adenine dinucleotide(NAD) | 53-84-9 | Moligand™, ≥95%(HPLC) | |
β-NADH | 606-68-8 | 10mM in DMSO | |
β-NADH | 606-68-8 | ≥95% | |
β-NADH | 606-68-8 | ≥98% | |
NADP, Disodium Salt | 24292-60-2 | 10mM in Water | |
NADP, Disodium Salt | 24292-60-2 | ≥97% | |
NADPH | 2646-71-1 | ≥93% | |
β-Nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt hydrate（β-NADPHtetrasodium salt hydrate） | 2646-71-1 | ≥97%(HPLC) | |
Coenzyme II reduced tetrasodium salt | 2646-71-1 | ≥95% | |
β-Nicotinamide Mononucleotide(NMN) | 1094-61-7 | ≥95% | |
β-Nicotinamide Mononucleotide (NMN) | 1094-61-7 | 10mM in Water | |
β-Nicotinamide Mononucleotide(NMN) | 1094-61-7 | ≥99.5% | |
Nicotinamide riboside chloride( NR-CL) | 23111-00-4 | ≥99.5% | |
Nicotinamide riboside chloride( NR-CL) | 23111-00-4 | ≥98% | |
Nicotinamide Riboside Chloride (NIAGEN) | 23111-00-4 | 10mM in DMSO | |
Nicotinamide | 98-92-0 | ≥99.5%(HPLC) | |
Nicotinamide | 98-92-0 | ≥99% | |
Niacinamide | 98-92-0 | PharmPure™, USP | |
Nicotinamide | 98-92-0 | for cell culture, suitable for insect cell culture, ≥99.5%(HPLC) | |
Nicotinamide | 98-92-0 | analytical standard, ≥99.8% | |
Nicotinamide (NSC 13128) | 98-92-0 | 10mM in DMSO | |
Niacinamide solution in Methanol | 98-92-0 | 100μg/mL in Methanol, Uncertainty:3% | |
Niacinamide solution in Methanol | 98-92-0 | 1000μg/mL in Methanol, Uncertainty:2% | |
Nicotinic acid | 59-67-6 | PharmPure™, USP | |
Nicotinic acid | 59-67-6 | Moligand™, for synthesis | |
Nicotinic acid | 59-67-6 | Moligand™, for cell culture, suitable for insect cell culture, ≥99% | |
Nicotinic acid | 59-67-6 | Moligand™, suitable for plant cell culture, ≥99% | |
Nicotinic acid | 59-67-6 | Moligand™, ≥99.5%(HPLC) | |
Nicotinic acid | 59-67-6 | Moligand™, ≥99% | |
Nicotinic Acid | 59-67-6 | Moligand™, 10mM in DMSO | |
Nicotinic acid | 59-67-6 | Moligand™, analytical standard, ≥99.5%(HPLC) | |
Nicotinic acid mononucleotide | 321-02-8 | ≥95% | |
Nicotinic acid adenine dinucleotide sodium salt (NAAD Na) | 104809-30-5 | Moligand™, ≥98% | |
L-Tryptophan | 73-22-3 | Moligand™, 10mM in DMSO | |
L-Tryptophan | 73-22-3 | Animal Free, USP, JP, Moligand™, Ph.Eur.（Ph.Eur）, for cell culture, ≥99% | |
L-Tryptophan | 73-22-3 | Moligand™, ≥99% | |
L-Tryptophan | 73-22-3 | PharmPure™, USP, JP, BP, Ph.Eur. | |
L-Tryptophan | 73-22-3 | UltraBio™, ≥99.5%(NT) | |
2,3-Pyridinedicarboxylic acid | 89-00-9 | ≥98% | |
2,3-Pyridinedicarboxylic acid | 89-00-9 | ≥99% | |
2,3-Pyridinedicarboxylic acid | 89-00-9 | 10mM in DMSO |
In cellular systems, NAD plays two key roles simultaneously—as a redox cofactor and as a regulatory cosubstrate—making it both a universal interface of metabolic networks and a flux node for homeostatic regulation. For applied research, the main line should be the flux balance among synthesis, consumption, and recycling, integrating tissue distribution, organ hub effects, and methodological control points. For intervention strategies, the mechanistic differences between stimulating synthesis and inhibiting excessive consumption should be clarified, and a verifiable evidence chain should be established using tiered molecular–functional–safety endpoints, thereby maintaining scientific rigor and reproducibility in mechanistic interpretation and translational expression.
For more related articles, please see below:
[2] NADH vs NADPH: Homologous coenzymes with distinct functional specialization
Aladdin: https://www.aladdinsci.com/